Novo Nordisk A/S (US6701002056)
Gesundheitswesen | Allgemeine Arzneimittelhersteller

50,70 EUR

Stand (close): 09.01.26

Nachrichten

Datum / Uhrzeit Titel Bewertung
12.01.26 22:45:00 Drei Einzelhandels-Trends, die man 2026 beobachten sollte, laut NRF 2026
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** **Zusammenfassung:** Die Nationale Einzelhändlervereinigung (NRF) veranstaltete auf ihrer „Retail’s Big Show“ in New York City eine Reihe wichtiger Trends, die das Einzelhandelsgeschäft im Jahr 2026 prägen werden. Künstliche Intelligenz (KI) ist als transformativer Faktor auf dem Vormarsch und Partnerschaften zwischen Google’s Gemini und großen Einzelhändlern wie Walmart und Shopify nutzen Chatbots und verbesserte Kundenerlebnisse. Experten prognostizieren einen Wandel von der KI, die dem Verbraucher zugewandt ist, hin zu betrieblichen Veränderungen im Hintergrund, wie KI-Agenten miteinander kommunizieren und Einzelhandelsprozesse optimieren werden. Verbraucher passen sich bereits an konversationelle KI-Plattformen wie ChatGPT an, was auf eine erhebliche Veränderung des Kaufverhaltens hindeutet, dem Einzelhändlern gegenüber. Ein großes Anliegen für Einzelhändler ist die zunehmende Akzeptanz von GLP-1-Gewichtsverlustmedikamenten. Analysten prognostizieren einen dramatischen Anstieg der Nutzung – von 9 % der US-Haushalte im Januar 2025 bis zu einer geschätzten 20 % bis Dezember 2025 – angetrieben durch die orale Darreichungsform des Medikaments. Diese Verschiebung hat Auswirkungen auf die Konsumausgaben, mit einer bemerkenswerten Verringerung der Lebensmittel- und Getränkeausgaben, einem Wandel hin zu Wellness-bezogenen Ausgaben (Fitnessstudio-Mitgliedschaften, Reisen, Athleisure-Kleidung) und einer Präferenz für engere Kleidungsstücke. Einzelhändler erkennen diesen Trend als bedeutende demografische Chance an und zielen darauf ab, Verbraucher auf ihren Wellness-Wegen zu unterstützen. Der Anstieg dieser Medikamente wird mit technologischen Disruptionsereignissen wie dem iPhone verglichen, wobei Verbraucher ein gesteigertes Selbstvertrauen und Klarheit erleben. Neben KI und GLP-1s betont der Bericht weiterhin das anhaltende Verlangen der Verbraucher nach Wert. Einzelhändler beobachten ein erhöhtes Interesse an erschwinglichen Luxusartikeln, wie es sich aus Panel-Diskussionen mit Marken wie Beyond Yoga, Miss Jury und sogar Windelmarken wie Corelle gezeigt hat. Verbraucher, unabhängig von ihrem Einkommensniveau, sind bereit, in Produkte zu investieren, die sie als echtes Wertversprechen wahrnehmen. Das Gespräch auf der „Retail’s Big Show“ deutet auf einen bedeutenden Anpassungsprozess für die Einzelhandelsbranche hin. Einzelhändler erkunden, wie sie KI nutzen können, um Kundenerlebnisse zu verbessern und Abläufe zu optimieren, während sie sich den sich ändernden Konsumentenlandschaften stellen, die von medizinischen Fortschritten wie GLP-1s und einem neuen Fokus auf das persönliche Wohlbefinden beeinflusst werden. Der Bericht besagt, dass erfolgreiche Einzelhändler diejenigen sind, die agil genug sind, um auf diese sich entwickelnden Trends zu reagieren und die spezifischen Bedürfnisse und Vorlieben dieser sich entwickelnden Kundengruppe zu erfüllen. Die Auswirkungen erstreichen sich über mehrere Sektoren, darunter Lebensmittel, Reisen und Wellness, was einen wirklich disruptiven Wandel im Konsumentenverhalten und der Einzelhandelsstrategie darstellt.
12.01.26 17:29:00 Gesundheitscheck-Runden: Markentalk
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** **Zusammenfassung:** Die aktuellste "Market Talks"-Berichterstattung bietet Analysen und Einblicke in wichtige Bereiche des Gesundheitssektors, darunter die finanzielle Lage US-amerikanischer Pharmaunternehmen und der Zustand der thailändischen Gesundheitsversorgung. --- Would you like me to: * Adjust the tone of the German translation? (e.g., more formal vs. informal) * Provide a slightly different version of the summary?
12.01.26 16:34:46 Nvidia und Eli Lilly investieren 1 Milliarde Dollar in ein KI-Labor zur Arzneimittelforschung.
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** **Zusammenfassung:** Nvidia und Eli Lilly planen gemeinsam eine Investition von 1 Milliarde Dollar, um ein neues, auf KI-gestütztes Forschungslabor in San Francisco zu errichten. Diese Zusammenarbeit zielt darauf ab, die Arzneimittelforschung durch die Nutzung der Rechenleistung und der Expertise bei der Erstellung von KI-Modellen von Nvidia sowie der umfangreichen biologischen und medizinischen Daten von Lilly zu revolutionieren. Das fünfjährige Projekt konzentriert sich auf die Erzeugung großer Datensätze und den Aufbau von KI-Modellen, um die Entwicklung neuer Medikamente zu beschleunigen. Die Partnerschaft baut auf einer bestehenden Vereinbarung auf, in der Lilly Nvidia’s KI-Systeme bereits nutzt, um seine Arzneimittelforschungsabläufe zu beschleunigen. Lilly’s Aktienkurs ist in den letzten Monaten erheblich gestiegen und hat den S&P 500 übertroffen, was das Vertrauen der Investoren widerspiegelt. Nvidia, ein globales Vorreiterunternehmen, wird derzeit mit über 5 Billionen Dollar bewertet. Diese Initiative spiegelt eine breitere Tendenz zur KI-Investition in verschiedenen Branchen, insbesondere im Bereich der Life Sciences wider. Nvidia, zusammen mit Lilly, arbeitet auch mit anderen Schlüsselakteuren wie Novo Nordisk und der Mayo Clinic zusammen und setzt KI in der medizinischen Forschung und Entwicklung ein. Jensen Huang, CEO von Nvidia, betonte das transformative Potenzial von KI im Life Sciences Sektor. Die Investition unterstreicht die wachsende Anerkennung von KI’s Auswirkungen und die strategische Bedeutung ihrer Integration in die pharmazeutische Forschung, während sie gleichzeitig Bedenken hinsichtlich einer Überinvestition und möglicher KI-Blase auf dem Markt aufwirft.
12.01.26 11:43:00 An Investor's Guide to 2026
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** In this podcast, Motley Fool analyst Emily Flippen and contributors Travis Hoium and Lou Whiteman discuss: The AI trade.How the economy is doing.Where certain stocks might be headed. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10 list of stocks to buy. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks » A full transcript is below. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 968%* — a market-crushing outperformance compared to 197% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you joinStock Advisor. See the stocks » *Stock Advisor returns as of January 12, 2026. This podcast was recorded on Jan. 02, 2026. Travis Hoium: The calendar is flipped to 2026, so where are we investing? Motley Fool Money starts now. Welcome to Motley Fool Money. I'm Travis Hoium joined by Lou Witman and Emily Flippin. Since the calendar has now moved to 2026, we're recording this a couple of days early so that we can have a little bit of time later in the week. But we are thinking a lot about how we're investing in 2026, what the economy looks like, where there's value, maybe, where we should be selling a little bit. I want to start with a couple of different themes, and the biggest theme that we have to talk about this has been the topic of the market for the last three years. That's artificial intelligence. Where are you looking at the AI trade in 2026, Lou? You can take this in any number of different directions. Is there risk? Is there opportunity? Or is this just something that you're monitoring from the sidelines and going, you know what, this is accounting for 50% of GDP growth. That's a pretty notable change in the way that we think about AI. Lou Whiteman: The first thing is, it's 2026, and wow, we're still doing this instead of AI. Cheers to us for that. Travis Hoium: The disruption has not hit us yet. Lou Whiteman: Yeah, not yet. Famous last words. What strikes me about AI, and I've been thinking about this a lot is, the novelty is over. The magic has gone. When ChatGPT first came on the scene, and it was, wow. It was magic. It was all this talk about virtual friends, doing all these chores for us. Just what was new and magic before is now mundane. I think the answer from here is boring. I think this is going to be the year of the agents of all of this stuff. Travis Hoium: Was is 2025 supposed to be the year of agents? Lou Whiteman: Well, it was, and maybe that was the work. But here's what I think is happening here. Again, it's not going to be the cool magical stuff. They're not going to be planning our vacations or doing these wow tasks. But there is just all over the place. We're just at the tipping point where so many little automations, making so many little tasks, 10% better. I don't think that that is what we all hope for. Maybe the virtual friend, the imaginary friend is still coming, but I do think that matters. The theme this year, if it's a theme, it's specification over scale. It's no longer just this pure muscle do all things, but just creating small AIs that can just make life easier all over the place. I think that is going to be the theme for 2026 in AI. I think there is real good news for investors there because I think that this translates to revenue and profits better than the imaginary friend on our shoulder. Travis Hoium: It's interesting you put it that way because it seems like that would just be a continuation of the last 30, 40 years in computing and software. Is that the way that you're thinking about AI now and not just we're all going to be. We're not going to have to work anymore the way that Elon Musk says, because robots or whatever are going to be doing everything for us. Is it just going to be more of an incremental technology improvement, the way that we've seen mobile phones, and PCs, and Excel spreadsheets and things like that, make things that used to be commonplace in the '70s, '80s, '90s become just more efficient. Is that the right way to think about AI? Lou Whiteman: That's a dangerous question because it's open ended. I never want to say no to something if you give a long enough timeline. But, yeah, I think you hit it on the head. This is how progress works. Progress is not flashy. Progress is not wow. Progress is incremental. Maybe we will get to that vision. I don't think it'll be nearly as quickly as the pundens or the wow what you think. I think just incremental improvement is how tech works when it works. Travis Hoium: Emily, when you look at artificial intelligence, where are you looking at real business models being created? Again, where does that risk reward lie? Emily Flippen: Yeah, I love that point. To use earlier comment about us still doing this as humans, not being replaced by AI yet. I think part of the reason is because we're willing to go out there a little bit and come here with some takes that maybe wouldn't be generated by a chatbot, and then you can hold me and Lou accountable for them a year from now when they inevitably end up wrong. But to your point, Travis, it's not so much about creating new businesses. It's about evolving the business models that exist today. The thing that I'm watching with AI in 2026 is actually advertising. I think that's the midterm game for AI and AI centered companies or companies that are looking to implement it. It's not the data centers. It's not the CAPEX. It's not enterprise usage. I think it's characterized by what the Magnificent 7 and large tech companies are going to do with advertising as it relates to artificial intelligence. There's only two of the Magnificent Seven and Nvidia and Tesla that aren't dependent upon advertising revenue as a source of sales. I'd actually argue that Nvidia by proxy is actually really heavily dependent on advertising, given the fact that its larger customer base needs to sell ads in order to afford the hardware. Travis Hoium: Explain that because I think OpenAI is really the big question here. They're obviously the elephant in the room. They're the ones with what is it now $1.5 trillion in spending plans. A lot of that is in video chips. But they don't have that advertising business model, but do they need it? Emily Flippen: They desperately need it. I think 2026 is the year where these individual consumers are going to start seeing ads and other integrations into their ChatGPT. It's not just ChatGPT, it's Gemini. It any company that has some large language consumer facing model is going to need to find a way to monetize the data that they have on the people using the application. Even if that comes alongside a subscription fee. To me, that screen ads. Without businesses generating ad revenue, they obviously, to former point, can't afford hardware to continue to expand and grow their business and their data centers, which results and by proxy, a declining sales for Nvidia. But it's not just OpenAI. Look, you can look at Meta, another Mag Seven company. Virtually 100% of their sales are ad based sales. Google is like 75% plus of their sales are ads. All of these companies are really heavily dependent upon that. What's really interesting about the world advertising is it's a zero sum game, which is to say, just because OpenAI comes out and says, hey, you could put ads on ChatGPT now, just using that as one example. Does it mean that the ad budgets for companies that are buying placement suddenly increases. They still have a finite amount of money. Travis Hoium: Unless you've built out that, that's a longer game. Like the businesses that are built because Shopify and Facebook exist, but that doesn't happen in 2026. That's a five, 10 year story. Emily Flippen: Exactly. Hopefully, I mean, I expect the world for advertising demand for advertising, the advertising size of the market. That is going to grow over time to your point, Travis. But thinking about it from the perspective of an individual business, if I'm into it's one of those businesses that just loves to advertise, especially around this time of year as we get into tax season. If I'm into it, I'm not saying, I have new places to advertise. Therefore, my advertising budget for the entire year has increased proportionally to the number of places I can advertise. They probably still have a set budget. Let's say it's $100 million or whatever it may be. They say, maybe I put less of that with Meta. Maybe I put more of that with OpenAI. That's when it starts to get interesting for how these AI based companies are going to monetize and advertise, because it's not just about how effective ads are by usage of AI. It's actually how search and other interactions change as a result of where the money for ads is actually spent. Travis Hoium: Are you able to extract the same number of dollars? What's the margin? I think that's going to be another one of these questions because it is more expensive to compute with AI, than it is with traditional compute. We've seen that with margins at companies like Meta and Alphabet over a long period of time. One of the things that you touched on, Emily, that I think is interesting is are we at the point where this AI, in general, is proving to be much more of a sustaining innovation rather than a disruptive innovation. I think if you go back to that ChatGPT moment, you have stocks like alphabet dropping or going at least nowhere, despite the fact that they were growing revenue, because they thought that this was going to disrupt their business. This is going to disrupt search. It was how they make money. Are we at the point where we can say, you know what? There's going to be new businesses formed? This is going to be an opportunity for entrepreneurs, but it's not necessarily going to destroy a whole bunch of older tech businesses, the way that we saw disruption when let's say Google and Meta, Facebook came around that really destroyed the newspaper business. Is that the right way to think about it, at least where we sit today? Emily Flippen: I definitely think it is. What's so interesting about where we sit today versus where we sat even 20 years ago when we were going through the.com crisis then boom of the Internet. Is that companies and their leaders and their decision makers are not unaware of the threat of disruption. I think everybody has become more aware. Disruption almost implies the idea that you're being taken aback by something that you didn't see coming. AI isn't so disruptive because we have companies that could see the future, so to speak, but solve the exisential threat and then decided to innovate around it. It's to your point, much more sustaining than it is disrupting for these companies because they're investing in. Lou Whiteman: They can invest in it. That's the big thing. Like with the newspapers, they didn't have the resources. These companies have the resources to throw at the problem. Whether or not it makes everyone 100% a winner, I wouldn't say that, but I think that's the big difference is that so many of these companies have these virtual money printing machines that they can throw at the problem. Travis Hoium: Well, the constraints seem completely different. If you're a newspaper, you had a geographic constraint, that was your monopoly. Google's playing in the world. The global economy. AI is going to do the same. It's just a different shift, it seems like. Lou, I wanted to ask you about robotics, because this is one of the things that we often talk about with AI, and it's this amorphous thing in the future. I Robot was the way to play this for a while. Obviously, that didn't work out. But there are these moonshots that are happening, whether it's at Tesla. One of the companies I think is interesting that's still private is figure. Is humanoid robots. Is that going to be something that's going to start impacting the economy, whether we're buying them as consumers or businesses are adopting those products? Lou Whiteman: At least for 2026, I'm still very skeptical about the dancing robots. I don't think. This is going be similar [OVERLAPPING]. Travis Hoium: The videos are pretty funny, to be. Lou Whiteman: They're awesome. But this is going to be similar to my boring answer on AI. I don't think this right now is about Rosie the Robot from the Jetsons making us eggs or doing our dishes. But the great thing about AI, and I think we're going to hear a lot about robotics. We'll get to this in my radar stock, even just to teas. But the great thing about AI is that all of these robotics that we have and all this automation we have, we're mostly single function machine, one task machines. AI gives us the ability to make them multi function machines and to do more with the existing technology. Again, I don't think that ends up with a robot butler in 2026, but I think all over the automation world, what we can do with automation and what we can do with what we've already invested in is just going to really accelerate, and that is a huge productivity thing. It might not be fun for consumers, but it's great for us as investors because it does, I think, over time, move the productivity curve. Travis Hoium: I'm looking for a robot that will clean up after my kids. When that comes out, I will be an early adopter. When we come back, we're going to talk about the economy and what we think about jobs and where spending is going in the future. You're listening to Motley Fool Money. Welcome back to Motley Fool Money. We talked a little bit about AI, but look, none of this works, all the spending in AI doesn't really work if the economy tanks. There's some signs of strength in certain places, signs of weakness in others. Emily, where do you see the economy going into 2026? What's good? What's bad? What's just worth watching as the year plays out? Emily Flippen: I think I, like the average person, is very confused about what we're seeing today, which is to say that the data that we have is painting two entirely different pictures. If you just take the reported data at face value, it shows strong, real GDP growth that's rising and accelerating, driven largely actually by consumer spending. Inflation, while still higher than what the Fed wants, it's well managed, and it's inching downwards, and we're easing back to those Fed targets, and the economy is still adding jobs and mortgage rates have eased. But when I say that, I know the average listener is probably going, excuse me. That's not the reality that I'm living right now. Underneath the data, I think we have a lot of confusion. There's economists and even members of the Fed themselves that are doubting the data, which is to say not the numbers are inaccurate, but not paying the full picture, saying that inflation could be understated either due to the government shutdown or reporting metrics, tariff impacts are yet to show their true teeth. Layoffs are actually accelerating. Pal himself so that the jobs data could be overestimated to the extent that the US has actually been losing jobs through the majority of 2025. This is to say, it forces me to watch a lot more than I probably would want to when I head into 2026. What I'm having to do is look at ancillary data. Large scale layoffs or which companies are required to report. That's a great indicator of the job market. Credit spread or delinquencies show a lot about the average consumer as we expand to that K-shaped economy here in the United States. Obviously, CAPEX from big tech companies. These in my mind are like the canaries in the coal mine of the economy when you can't or won't or otherwise have doubts about the reported data. Travis Hoium: What is that K-shaped economy? We talk about a lot. But can you just explain what exactly that is? Because I think that will be important as we go throughout the year. Emily Flippen: A lot of people have summarized it as the declining middle class. But in effect, the way that we have seen the economy grow and expand over the course, especially over the last couple of years, but you can even expand it over to the past few decades, is that the rich get richer and the poor get poor to an extent. The people in the middle, so the average American who hasn't seen wage growth that matches inflation is effectively getting poor and poor. The big earners and the big spenders have been doing a lot to keep the economy afloat, which helps these reported numbers look good at face value because there's a subset of high spending, high earning Americans that are doing well. But a majority of Americans, those people who aren't seeing those raises or those increases are continuing to get worse year after year. Travis Hoium: I saw a recent stat that something like the top 10% of spenders actually account for almost 50% of spending. There is a have and have nots. Lou, what are you thinking right now? Lou Whiteman: Again, we have to put everyone in buckets because we can't look at the individual. But really, what we're talking about here is there's a lot of pressure on some people, but a critical mass of consumers are still employed, still spending, and really, we make decisions based on our own checkbook. As long as that critical mass is there, whether or not it's a carve out in a middle class or something, I think those are all, were some things to talk about. But the bottom line is, that as of right now, there are enough people spending to keep things going. The question is, where from here? Does all of the job talk and all of these, decative signs, does it build on itself slowly swallowing more consumers and breaking down that critical mass? Or do we see inflation ease, which helps with the jobs? All of a sudden, employment picks up, and that critical mass gets us through to the other side. It's really hard to know that. I think both are possible. You mentioned the data. The other thing right now is that, look, I don't even think you need to be a cynic to question the data right now. They are saying that they are making methodology choices, which might be correct. There has been forever debates about how we do economic data. But when you do that, when you make changes, it makes apples to apples comparisons really hard. I don't even think you have to be a conspiracy theorist to say, I don't know how to read the data. That makes life a lot harder for us we're trying to have an opinion or a prediction on where things are going. Travis Hoium: Lou, you may raise an interesting point about I think about this like a snowball. In 2008, 2009, when the economy got really bad, you'd have to go back to 2006, 2007, to see the start of this. How does that play out? Let's just talk about that downside risk. Layoffs, it isn't one layoff announcement tells us that a recession has begun or something like that. It's this trickle that becomes uncertainty for executives. I remember sitting listening to the CEO of 3M in, I believe it was 2008, saying, "We don't know where the bottom is, and so we're just going to cut as much as we possibly can." Because we don't want to be, SOL when we do hit that bottom is that the risk is that this snowball starts, maybe AI spending cuts back, and we just don't know where it goes. Lou Whiteman: Inevitably, we always swing too far in either direction. I think the risk, we started 2025, talk about the boiling frog economy that everything's fine till it's not. I think, heading into 2026 is just going to be that same theme where everything right now from an economic perspective, from a Wall Street perspective, is good enough. Wall Street doesn't have to act with Main Street. That's one of the first lessons you learn. The stock market is not the economy. The stock market has priced some of this pressure in. It's all fine till it isn't to your point, that when this critical mass, when we stop seeing just enough people doing their economic activity, keeping things going, that's the point where we're in trouble, and by then, it's probably too late to avoid at least some impact. Travis Hoium: Definitely a lot to think about with the economy and AI in 2026. When we come back, we are going to play a game called up or down. You're listening to Motley Fool Money. Welcome back to Motley Fool Money. In this section, we like to play a little game, and we're going to see what Emily and Lou think about some specific stocks. I'm going to call this up or down. The idea here is, do you think these stocks are going to beat the market in 2026 or not? I have 12 stocks on the list, and I have asked them to split their votes 50, 50. You can't just say everything is going to beat the market. Lou, I'm going to have you go first with arguably one of the most important stocks for the stock market because it is the biggest piece of the S&P 500, Nvidia. Are they going to beat the market or not in 2026? Lou Whiteman: An object in motion tends to stay in motion. I have them beating the market. Now, look, a huge caveat here. They've been going up well in excess to the market. All they have to do is go up, probably 78% to beat. I think Nvidia might do less well than it has the last few years, but still beat the market. Emily Flippen: That's a fair take, but I have to take the other end, say they'll lose to the market, and the only reason is, look, I'm rooting for Nvidia here. But to counter lose point about an object in motion, typically, historically speaking, the largest company in the world is not the largest company in the world when you zoom out to a three-year time period. Nvidia has already been the largest company through the majority of 2025, I can't help but think 2026 is probably going to be a high bar. Travis Hoium: Let's move way away from AI to a potential falling knife, Target. Emily, beat the market or not? Emily Flippen: Beat the market. Look, I've been meaning to buy target for the better part of the last year. I'm happy that I dragged my feet on that. I intend to make that purchase at some point in early 2026, but I think they can get the merchandising strategy, and if discretionary spin comes back, they're well positioned. Lou Whiteman: I'm going the other way just because I think there can be a turnaround, but it's going to take more than a year. In this context, I think one year is too short of a time frame. I'll also say, look, retail is really tough. Nobody has an inherent right to exist. Ask Sears. Even Coles, some of the problems. I'm worried about Target long-term, and I don't think even if they do recover, it will be as quick as 12 months. Travis Hoium: Let's go to another popular stock. Chipotle, Lou, are they going to make a comeback in 2026? Lou Whiteman: I think this is a tough year for fast casual. Again, I'm not going to write them off, but I have lose here just because I think that there's a lot of choppiness. I think in general, fast casual, there's just too many people chasing this audience now, so it's hard for any of them to really thrive. That doesn't mean it can't be a good business long-term, but I'll take them losing this year. Emily Flippen: I think Chipotle had a tough year this year because they're coming off some really strong comps in the post-pandemic period. In 2026, their comps are going to be a lot easier of a hurdle to jump over, and I think expectations are too low. I have them beating the market. What about another Travis Hoium: one that has confused me. This one could be up 100% or down 50%, but Intel, where are they going, Emily? Emily Flippen: This is such a hard one. I have a tepid lose to the market because when I look at the chip space, I just don't know if they're the leader that they need to be to sustain market beating performance, but it's a tepid lose. Lou Whiteman: I have a tepid beat because I don't know what to think, too, and it's weird to live in a world where I'm not sure we even need Intel. Imagine saying that 10 years ago, but I do think they have the backing of the full faith and credit of the US government. They have that. They just closed the investment with Nvidia. I do think there's wind at their back. Long-term, I'm not sure I want to own this. I don't know where they shake out, but I think it'll be a better 2026 for them. Travis Hoium: What about another consumer company? In this gets to what we talked about earlier. What are consumers doing? Are they spending or are they not Lou, Lululemon? Lou Whiteman: This is another one that I need to caveat that, to me, a year, it doesn't tell the whole story. I think they do beat. I think whatever momentum comes out of this proxy fight and the new CEO, I think there will be encouragement. I worry about this company long-term as far as getting its mojo back. But I think for 2026, there probably vibes go its way. Emily Flippen: I'm a lot less worried than Lou, but I do agree that I think Lululemon beats over the course of the next year. Now, there have been a lot of macro changes that have impacted them, both in terms of competition and fashion trends, but there is no doubt in my mind that Lululemon can work out their merchandising strategy, and I don't think that their brand has deteriorated to the point where it hurts their sales. Travis Hoium: Lululemon's stock is down 45% over the past year. I think that would have been a shocker coming into the year. We'll see if there's some value there 15 times earnings. I don't know. Is that a value or a value trap? We'll have to see. That'll be a fun one to talk about. Along the same lines, Emily, is Nike going to make you come back? This is almost the same story, but just a different brand. Emily Flippen: It is to an extent, and I have different answers here. I think Nike loses to the market. My concern with Nike is I actually don't see any desire to innovate to the extent that they need to to edge out the competition. When I see companies like ON Holdings just continuing to eat Nike's own lunch, I get really worried about the long-term viability of the brand. Lou Whiteman: Look, it's just a different market. It's so much more of a crowded market. To me, I think the company can be fine and the stock cannot be fine, and so I'm lose, too. I think that this is just running to standstill, so to speak. Travis Hoium: It's wild to think that Nike has become a little bit like Under Armour for us when we shop for gear for the kids, especially, that's Nike's where you find good deals. That's a tough spot to be in if you're in the consumer space. Let's go to AI, robotics,electric vehicles, autonomy, whatever you want them to be. Emily, is Tesla going to beat the market or lose to the market in 2026? Emily Flippen: This is where the time frame catches up to me here, because here's what I'll say about anybody who's investing in Tesla. You're not doing so because you think it's going to do well in 2026. You're doing so because you think a decade, two decades, 50, 100 years from now, Tesla is going to continue to be an innovator that is leading the way in whatever it may be robotics, cars, you name it. I actually have Tesla losing to the market over the course of 2026, and the reason is pretty obvious, in my opinion, we've seen a decline in demand for electric vehicles. A lot of tax credits have rolled over. There's a lot of stiff competition from international sales, especially, lots of near term headwinds for Tesla. But does that change anything for the long-term investor? Probably not. Lou Whiteman: Spot on. I don't have much to add. Tesla, there's a lot of headwinds for this year, but I don't think that affects the bull case at all, so I'm losing too. Travis Hoium: Are either of the two of you going to be in a Robotaxi with no safety driver in 2026? Lou Whiteman: No. Emily Flippen: Personally? Probably not. Travis Hoium: That's the theory, though, is that they're supposed to be doing that? It's supposed to be by the end of this year. Emily Flippen: 2027 is always just around the corner. Travis Hoium: It is. Next year is always just around the corner for Tesla. Alphabet, this was the surprise one that beat the market in 2025. Lou, is it going to do the same in 2026? Lou Whiteman: This is similar to Nvidia for me. I think that they are a leader, and I think they will remain a leader, and so I'm going to have them beating, but I don't think it's going to be a wow beat. I think a lot of that catchup was this year. But I don't think advertising or anything they're doing is going to fall off a cliff, and I do think that they're a pretty good bet to just beat what I think could be a boring market in '26. Emily Flippen: I completely disagree, and I love that. I have Alphabet losing to the market because I do think that advertising risks falling off a cliff in 2026. Now, they've been heavily investing in Gemini and their own AI ambitions, which is important, but what they're doing is fighting to retain the three quarters of their revenue that comes from advertising. They need that to succeed, and they need no competition to take even at the margin a portion of their ad sales. I have a lot of reasons to believe that in terms of the ad revenue that's going to be headed toward Alphabet in 2026 is going to be less than what it was in 2025. Travis Hoium: Emily does that extend over to a company like Meta, too? Emily Flippen: Certainly does. Meta, I will say, the difference between the Alphabet and the Metas of the world is that Meta has better click-through rate ROI for an advertiser than a lot of Alphabet platforms. Withholding YouTube, that's the wildcard, in my opinion. We don't have a lot of data about how well ads convert on YouTube. You have to imagine pretty darn well, considering the performance of Alphabet, but that could be the saving grace here. Travis Hoium: I have to throw in one of the most talked about stocks on the market, trading for 111 times sales. Emily, will Palantir beat the market this year? Emily Flippen: What a read? You have to say that right before I about to tell you that I do think Palantir is going to beat the market. My reasoning is not sophisticated, it's not based off the fact that I think it should be trading for 200 times sales. It's that I see no fundamental changes in their core client base and government spending over the course of the next year, I have reason to believe that there'd be a rerating on the stock and the near term. Travis Hoium: The vibes will remain high. Emily Flippen: The vibes are high. Lou Whiteman: I think Emily has the right answer there, and I just still can't get my head around it, so I have lose just because on all the history of me looking at stocks, I don't think there is a valuation that was harder for me to understand. I'm just going to assume that it's not sustainable, although as Emily says, I don't know what's changing. Travis Hoium: Historically, buying stocks at 100 times sales doesn't work out well. It has for Palantir's investors, so it has confused me, and hopefully for them, I will be wrong again in 2026. Let's go to another popular company. I'm going to give you a couple stats here about Apple. Over the last three years, the revenue has grown at a compound annual growth rate of 1.8%. Their price to earnings multiple is 36, and yet, over that period of time, three years, their stock is up 110%. Lou, are they going to continue their market beating ways? Lou Whiteman: I think they will. Again, I don't think it's going to be a crazy great year, but I do think that they are finally getting AI which is, let's just get someone's AI on our phones. I do think that will help support maybe not this huge super cycle, but continued sales. Apple is the definition of fine. Travis Hoium: What an inspiring call from Lou. Lou Whiteman: I wish I had more. I wish I knew what the next big thing was, but I think Apple just will continue to be Apple. That's the safest prediction I'll make. Travis Hoium: Fair enough. Emily? Emily Flippen: I completely agree with Lou. I think Apple beats the market. Maybe it's a bit higher conviction than Lou has, though. If I don't think Nvidia is going to be the largest company in a year, I think it's probably going to be Apple. For all the reasons Lou mentioned, Apple, I think, out of all the MAG 7 companies, is the most disciplined with its capital management. They haven't over invested in AI, but they also haven't been sitting on their hands with regards to it. The upgrade cycle is still really strong for this company, and they're not heavily dependent upon services or advertising more so than their on hardware. I think it's a lot easier to motivate consumers to upgrade, even in the environment we're operating in, as opposed to heavily relying upon software. Travis Hoium: I may help Apple in 2026, a computer, a new iPhone, probably on my list at some point in the year. Lou, what about Amazon next year? Lou Whiteman: Again, I have this as a beat. In part, Travis, because you made us even up our beats and misses, and this was the one I was on the fence about. I will say I'm on the fence. Amazon has a lot of CapEx in a lot of their business, and they have a lot of low margin, but AWS is just AWS, and I think that's enough to drive this truck forward. Emily Flippen: I also have Amazon as a beat. I'm not doubting myself as I think about it. The logic at the time when I want to consider this is Amazon is well positioned regardless of the market environment we're operating in. AWS does generate a sizable portion of their operating income. That's enterprise spending. Consumers generally go to Amazon for low-cost goods when they're shipping or changing where they shop, Amazon still gets a big portion of that. I do have some concerns for Amazon in regards to the CapEx, though, and a muted free cash flow year could be bad for them. Travis Hoium: They also have a huge advertising business. That accounts for a vast majority of the profitability for the retail business. Emily Flippen: Yes, around 10% of sales and the retail business is low margin to begin with, so the margin that's coming from ad placements is good for them. But I will say, those are ad placements that I think again, convert really well for the people who are advertising on amazon.com and other platforms that I see less existential threat from versus the search engines. Travis Hoium: Emily, are you seeing value in Airbnb, or will this continue to be a market loser? Emily Flippen: I unfortunately view it as a market loser over the next year. I do hope that I'm wrong, but there's some skepticism built in for Airbnb. They changed their policy in regards to upfront payments for a lot of their member base, so they get this strong high margin interest income on revenue that they collect at the time of booking, even if they end up having to give that back to the person in case of cancellations or refunds. That margin has been really profitable for them. Interest rates are coming down, which is hurtful, but they also change that policy, so less people are paying upfront, which also impact some of their high margin revenue. I don't see any other massive tailwinds here that would cause their sales to otherwise be market beating, and I don't know where they're going to make up for the margin on that. In my mind, I think it's a great company and probably fine as an investment, but I don't view it as a market beater in the next 12 months. Lou Whiteman: I'll admit I'm biased because I just came from an Airbnb, and I had all of the eye rolls that you get when you're at an Airbnb, just all the little things. But I think Emily said it best. There's another one of these just love the company, love the business, but I don't know where market beating growth comes from, so I had them losing to the market. Travis Hoium: When we come back, we are going to talk about some more stocks on our radar. You're listening to Motley Fool Money. As always, people on the program may have interest in the stocks they talk about and the Motley Fool may have formal recommendations for or against, so don't buy or sell stocks based solely on what you hear. All personal finance content follows the Motley Fool's editorial standards, and it's not approved by advertisers. Advertisements are sponsored content and provided for informational purposes only. To see our full advertising disclosure, please check out our show notes. One of the things I wanted to bring up quickly here at the end is commodities. This has been a hot topic over the past month. Gold outperformed the S&P 500 this year. Emily, how are you thinking about commodities going into 2026? Emily Flippen: I'm not thinking about commodities in 2026, maybe that's a hot take, but I think it's a mistake to assume that just because a commodity moves, it's a recession indicator. The classic example is the inverted yield curve, which is what predicted 10 of the last three recessions. There's so many different factors that impact commodity pricing. Some people may view gold as a safe haven, but silver and other commodities are obviously have industrial usage. Demand for gold was driven largely by central banks recently. There's so many different factors here, and I don't view them as investment so much as for an individual investor, a panic button and a lot of places, even though core demand is driven by lots of other factors. When I look at the actual track record, which is episodic at best and misleading at worst, it's not something that makes you want to pay attention. Lou Whiteman: Agreed. I think, if anything, it's geopolitical, and we don't have to get into that now, and it doesn't mean the end of the world. It doesn't mean the end of the dollar. One piece of advice, though, I don't know if it'll continue or not, but if you do think so, just buy the metals, buy the ETFs. I've seen so many people saying it's time to buy the miners. Mining is really hard, and mining stocks traditionally have not gone well. Please do your homework. Just buy an ETF with metal if you believe in the metal. Don't just start buying penny stock, copper mines or silver mines, please. Travis Hoium: This is a much more complicated area than a lot of people think, and there are people that spend their entire lives just looking at metals, whether it's gold, silver. Maybe not something for everyone to just jump in, but definitely something to watch in 2026. We like to end the show with stocks on our radar, and I'm going to give you some thoughts. Lou, you are up first. What's on your radar this week? Lou Whiteman: Travis, one of the stocks I find most intriguing heading into 2026 is Honeywell. Ticker HON. For a while now, this has been a great group of businesses that somehow haven't worked together as far as stock gains. Times are changing. Honeywell has already split off its advanced materials business. It's now Solstice, I think it is. It's already trading publicly. This year, 2026, they will separate the remaining businesses, Aerospace and Automation into two independent companies. These are all very interesting businesses on their own. I'm hoping thinking we might see something similar to what happened at GE. Another multi-year disappointing conglomerate split itself in three. We saw the strength of these businesses, and the parts have all taken off. Honeywell, and its many pieces I'm really watching in 2026. Really intrigued. Travis Hoium: If I have to pick one Solstice Honeywell Automation and Honeywell Aerospace, which one should I be looking at? Lou Whiteman: We talked about robotics before. The automation business is a lot of the tools behind that. That and Aerospace are probably the two that I might want to add to my portfolio one day. Travis Hoium: Emily, what's on your radar? Emily Flippen: I know this is going to be a hard sell for you, Travis, but hear me out. Novo Nordisk, the ticker NVO is on my radar. This is the Danish drugmaker who's best known for making Ozempic and Wegovy, and there's so much skepticism on this company right now. A lot of it earned, but I think at this point, has become entirely overdone. They are losing to Eli Lilly in the interim, and there's issues around reimbursement, obviously really expensive. But I do think that Novo Nordisk has one of the most effective methods of weight loss on the market today with a strong pipeline of new drugs and a lot of potential of your treatments associated with semaglutide, which it mostly still has on her patents. I think there's opportunity left in front of this company that investors are just writing off. Travis Hoium: GLP ones are about half of Novo Nordisk's revenue. As more and more of these products hit the market, we've got the oral product coming. It just seems like there's more and more competition. Is that a worry that both sales growth and also margins are going to be impacted negatively? Emily Flippen: That's certainly what the market is pricing in today, but I will say, the reason why these concerns exist around competition and pricing is because demand is so high. There are so many people that can benefit from these drugs that don't have access to them. Prices should and rightfully will come down, but I still think demand will be there for Novo Nordisk. Travis Hoium: Emily, I'm sorry, but with Honeywell hitting at least splitting off that automation business, I'll give Lou the nod here, but I'll at least take a look at Novo Nordisk. An interesting space for 2026. That's all the time that we have. Thanks to Emily and Lou and Bart behind the glass, I'm Travis Hoium. Thanks for listening to Motley Fool Money. Emily Flippen, CFA has positions in Airbnb. Lou Whiteman has positions in Nike. Travis Hoium has positions in Airbnb, Alphabet, Intel, and On Holding and has the following options: long December 2027 $50 puts on Palantir Technologies. The Motley Fool has positions in and recommends 3M, Airbnb, Alphabet, Amazon, Apple, Chipotle Mexican Grill, Honeywell International, Intel, Lululemon Athletica Inc., Meta Platforms, Nike, Nvidia, On Holding, Palantir Technologies, Target, and Tesla. The Motley Fool recommends Novo Nordisk and Under Armour and recommends the following options: short March 2026 $42.50 calls on Chipotle Mexican Grill. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
12.01.26 09:45:21 Aktuelle Schlagzeilen: Walmart, Alibaba, Novo Nordisk, BE Semiconductor und British Land
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** Okay, here's a 600-word summary of the provided text, followed by a German translation: **Summary (600 Words)** The provided text outlines several key market movements and company news stories on January 9, 2024. The overarching theme is the impact of artificial intelligence (AI) and evolving competitive landscapes within various industries. **Walmart & Google’s AI Partnership:** Walmart (WMT) shares rose 1.6% following a partnership with Google (GOOG, GOOGL) centered around integrating Walmart’s shopping capabilities into Google’s Gemini app. This partnership aims to allow customers to find and purchase products through a conversational AI interface – essentially, shopping via chat. The collaboration, announced by Walmart’s new CEO John Furner and Google’s Sundar Pichai, envisions an "agent-led commerce" future for retail, driven by AI assistants. Walmart and Google intend to initially launch the feature in the US, with broader international expansion planned. **Alibaba Investigation & Industry Consolidation:** Shares in Alibaba (BABA, 9988.HK) surged 5% following an antitrust investigation by China’s top regulatory body into the practices of major food delivery platforms. This signals a potential shift towards greater regulatory oversight and an end to the aggressive subsidy-driven price wars that have characterized the sector. The investigation is expected to curb excessive discounting and foster increased compliance costs for new entrants, ultimately benefiting industry margins. **Novo Nordisk’s Wegovy Expansion:** Novo Nordisk (NVO, NOVO-B.CO) saw significant share increases (7%) due to Amazon Pharmacy’s decision to offer Wegovy, Novo Nordisk’s blockbuster weight loss pill, through insurance plans and a cash payment option. This expands accessibility and provides a convenient alternative to injectable versions, potentially boosting Novo Nordisk’s sales. The FDA approval of Wegovy last December played a crucial role in this development. **BE Semiconductor’s Strong Quarter:** BE Semiconductor (BESI.AS), a Dutch chip equipment manufacturer, experienced a dramatic increase in orders (105% year-over-year) in Q4, leading to a 7% share rise. This growth was fueled by increased demand from Asian subcontractors and renewed capacity investments in the photonics sector. The company revised upwards its guidance for the fourth quarter performance. **British Land’s Leadership Change:** Shares in British Land (BLND.L) dipped over 2% following the announcement that CEO Simon Carter would be stepping down to lead P3 Logistics Parks. This transition signifies a shift in leadership and highlights the evolving dynamics within the real estate sector. **Key Takeaways:** The market movements reflect several trends: the rising importance of AI in retail and commerce, increasing regulatory scrutiny in China's market, expansion of pharmaceutical products, and shifts in leadership roles within major companies. The figures quoted demonstrate significant market sentiment surrounding these developments. The market is keenly watching for the implementation of these new technologies and their impact on profitability and market share. --- **German Translation (approx. 600 words)** **Zusammenfassung (600 Wörter)** Der bereitgestellte Text fasst mehrere wichtige Marktbewegungen und Unternehmensnachrichten vom 9. Januar 2024 zusammen. Das übergeordnete Thema ist der Einfluss künstlicher Intelligenz (KI) und die sich entwickelnden Wettbewerbslandschaften in verschiedenen Branchen. **Walmart und Google’s KI-Partnerschaft:** Die Aktien von Walmart (WMT) stiegen um 1,6 % nach einer Partnerschaft mit Google (GOOG, GOOGL), die sich auf die Integration der Einkaufsmöglichkeiten von Walmart in die Google Gemini App konzentriert. Diese Partnerschaft zielt darauf ab, es Kunden zu ermöglichen, Produkte über eine konversationelle KI-Oberfläche zu finden und zu kaufen – im Wesentlichen das Einkaufen über Chat. Die Zusammenarbeit, angekündigt von Walmarts neuem CEO John Furner und Googles Sundar Pichai, sieht eine zukünftige „agentenbasierte Commerce“-Ära im Einzelhandel vor, die von KI-Assistenten angetrieben wird. Walmart und Google beabsichtigen zunächst die Funktion in den USA einzuführen, mit einer umfassenderen internationalen Expansion, die geplant ist. **Alibaba-Untersuchung und Branchenkonsolidierung:** Die Aktien von Alibaba (BABA, 9988.HK) stiegen um 5 % nach einer Untersuchung durch die chinesische Aufsichtsbehörde in die Praktiken führender Food-Lieferplattformen. Dies deutet auf eine mögliche Verschiebung hin zu größerer regulatorischer Kontrolle und dem Ende der aggressiven, auf Subventionen basierenden Preiswetten gegeben hat, die den Sektor geprägt haben. Die Untersuchung soll übermäßige Rabatte und eine verstärkte Compliance für neue Marktteilnehmer eindämmen und letztendlich die Branchenmarge verbessern. **Novo Nordisk’s Wegovy-Expansion:** Novo Nordisk (NVO, NOVO-B.CO) erlebte deutliche Aktiensteigerungen (7 %) aufgrund der Entscheidung von Amazon Pharmacy, Wegovy, Novo Nordisks Blockbuster-Gewichtsverlustpille, über Versicherungspläne und eine Barauszahlungsoption anzubieten. Dies erweitert die Zugänglichkeit und bietet eine bequeme Alternative zu injizierbaren Versionen, was Novo Nordisks Umsätze potenziell ankurbeln könnte. Die FDA-Zulassung von Wegovy im Dezember spielte eine entscheidende Rolle in dieser Entwicklung. **BE Semiconductor’s Starkes Quartal:** BE Semiconductor (BESI.AS), ein niederländischer Halbleiter-Ausrüstungshersteller, erlebte im Q4 ein dramatisches Ansteigen der Bestellungen (105 % im Jahresvergleich), was zu einem Anstieg der Aktien um 7 % führte. Dieser Wachstum wurde durch gestiegene Nachfrage von asiatischen Auftragnehmern sowie durch erneute Investitionen in Kapazitäten im Bereich der Photonenik angetrieben. Das Unternehmen revidierte seine Prognose für die Leistung im vierten Quartal nach oben. **British Land’s Führungswechsel:** Die Aktien von British Land (BLND.L) fielen um mehr als 2 % nach der Ankündigung, dass CEO Simon Carter das Amt räumen wird, um die Leitung von P3 Logistics Parks zu übernehmen. Dieser Übergang symbolisiert einen Wandel der Führung und unterstreicht die sich entwickelnden Dynamiken im Immobiliensektor. **Schlüsselerkenntnisse:** Die Marktbewegungen spiegeln mehrere Trends wider: die wachsende Bedeutung von KI im Einzelhandel und im Handel, die zunehmende regulatorische Kontrolle in Chinas Markt, die Expansion von Pharmaprodukten und der Wandel der Führungskräfte in großen Unternehmen. Die angegebenen Zahlen zeigen eine deutliche Marktmoral in Bezug auf diese Entwicklungen. Der Markt beobachtet aufmerksam die Implementierung dieser neuen Technologien und ihren Einfluss auf Rentabilität und Marktanteil. --- Would you like me to adjust the translation or provide any further analysis based on the text?
11.01.26 16:03:00 This ETF Is Proof That the Healthcare Rebound Is Real
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** Caduceus symbol on trading floor with rising stock charts, highlighting healthcare stocks and market momentum. Key Points After years of trailing the S&P 500, health care has rebounded, leading all other sectors with a 19% gain over the past six months. The bullish case for that rally to continue involves America’s GLP-1 drug obsession and incredibly low health care stock valuations. The Vanguard Health Care ETF provides broad exposure and is off to a strong start in 2026. Interested in Vanguard Health Care ETF? Here are five stocks we like better. Prediction Market powered by With well-publicized losses for companies including UnitedHealth Group (NYSE: UNH), Elevance Health (NYSE: ELV), and Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO), the healthcare sector failed to outperform the broad market last year. In the three years prior to that, the sector finished with gains of just 2.6% in 2024 and 2.1% in 2023, and a loss of 2.0% in 2022. → NVIDIA’s Next Leg Higher May Have Started at CES But healthcare stocks have appeared to turn a corner. Over the past six months, the sector—which enjoys inelastic demand—has led all 11 sectors of the S&P 500 with a nearly 19% gain. According to investment professionals, the trend that began in mid-2025 is likely to continue into the new year. → MarketBeat Week in Review – 01/05 - 01/09 For shareholders of the Vanguard Health Care ETF (NYSEARCA: VHT), that is already proving to be true. 2 Major Catalysts for the Health Care Sector There are two major tailwinds that should help health stocks continue to enjoy this bullish momentum. One—the mass adoption of weight loss drugs—was partly responsible for the sector’s bullish reversal halfway through 2025. The other—comparatively low valuations—could continue to attract inflows as investors look to lock in profits and hedge against positions that present more inherent volatility. → This ETF Is Proof That the Healthcare Rebound Is Real America’s Weight Loss Treatment Craze Weight loss treatments including GLP-1 agnostics and semaglutide treatments such as Novo Nordisk’s products Ozempic as Wegovy are becoming widely adopted. At the same time, pharmaceutical companies are shifting from injectable treatments to pill form, while others, like Pfizer (NYSE: PFE), are doubling down on their investments in the weight loss market. Speaking on the popularity of these drugs, Catherine Brown, vice president of clinical services at digital health firm Welldo, recently told Reuters that “We're imagining these medications may become so common that everybody's got a GLP-1 app ... right there on your phone next to your bank account." Forecasts from industry consultancy firm Grand View Research indicate that the GLP-1 drug market could grow by a compound annual growth rate of 18.54% between 2024 and 2030, resulting in a global market value increase from $13.84 to $48.84 billion. Story Continues Low Healthcare Stock Valuations Are Attracting Inflows In the wake of President Trump’s tariff announcements in April 2025—trade policies that have had an adverse effect on imported pharmaceuticals—stocks operating in the health care sector have experienced almost comically low valuations, particularly when juxtaposed with the historically high valuations of tech and communication services stocks. Pfizer, for example, sports a trailing 12-month (TTM) price-to-earnings (P/E) ratio of 14.7, while Health benefits provider Elevance and Johnson & Johnson (NYSE: JNJ) have P/E multiples of 15.32 and 19.86, respectively. For context, tech favorites such as Palantir (NASDAQ: PLTR) and Tesla (NASDAQ: TSLA) have TTM P/E multiples of  421.11 and 290.53, respectively. In turn, it was only a matter of time until health care’s ratios caught the eye of value investors looking for opportunities at the tail end of 2025 and heading into 2026. In November 2025, Mizuho’s healthcare equity strategist Jared Holz told Barron’s that  “When you see money come out of a space, especially one that’s filled with trillion-dollar [tech] companies, it really doesn’t take much to get some of the underperforming sectors a little juice.” Vanguard’s VHT: A Basket of Undervalued Stocks The Vanguard Health Care ETF is up 2.30% this year after gaining more than 18% over the past six months. Much of those gains were fueled by rebounds and strong end-of-year performances from the fund’s top holdings. Those positions include the ETF's top five holdings: Eli Lilly (NYSE: LLY), AbbVie (NYSE: ABBV), Johnson & Johnson, UnitedHealth, and Merck (NYSE: MRK). Drilling down further into the holdings, VHT also has allocations to Pfizer, CVS Health (NYSE: CVS), which acquired health insurance giant Aetna on Nov. 28, 2018, and the United States’ largest hospital chain HCA Healthcare (NYSE: HCA). The ETF carries a negligible expense ratio of 0.09% while paying a dividend that currently yields 1.58%, or $4.64 per share annually. What Wall Street Thinks About VHT Based on analysts’ ratings of 23 companies in the VHT portfolio (64.3% of its total), the fund receives a Moderate Buy rating. Perhaps the strongest indication of Wall Street’s enthusiasm about the health care sector is the ETF’s current short interest of just 0.33% of the float, or less than 195,000 shares of the 60.17 million shares outstanding. That marks a nearly 37% decrease in short interest since the last reporting period. The article "This ETF Is Proof That the Healthcare Rebound Is Real" was originally published by MarketBeat. View Comments
11.01.26 14:55:00 Dieser Biotech-Titel könnte eine der besten Anlagen für 2026 sein.
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** **Zusammenfassung (ca. 500 Wörter)** Eli Lilly steht aufgrund seines wichtigsten Wachstumstreibers, Tirzepatid, vor weiteren starken Ergebnissen. Trotz zunehmender Konkurrenz auf dem expandierenden Markt für Gewichtsverlust bleibt der Ausblick des Unternehmens außergewöhnlich positiv. Der Artikel argumentiert, dass Investoren nicht durch aktuelle Bewertungswerte abgeschreckt werden sollten, und hebt das enorme Umsatzpotenzial des Medikaments sowie die robusten klinischen Studienergebnisse des Unternehmens hervor. Der Erfolg von Tirzepatid ist unbestreitbar. Als Wirkstoff in sowohl Mounjaro (für Typ 2-Diabetes) als auch Zepbound (für Fettleibigkeit) generiert er beeindruckende Umsatzzahlen. Bis zum Ende der ersten neun Monate von 2025 hatte Tirzepatid bereits 24,8 Milliarden Dollar eingenommen, übertraf damit Keytruda als das umsellteste Medikament der Welt. Experten prognostizieren Umsätze von fast 62 Milliarden Dollar bis 2030, was auf erhebliches zukünftiges Wachstum hindeutet. Dieser Erfolg basiert auf starken klinischen Studienergebnissen und Zulassungen durch die Aufsichtsbehörden, einschließlich für Schlafapnoe. Eli Lillys Wettbewerbsvorteil erstreckt sich über Tirzepatid hinaus. Die Entwicklung von Orforglipron, einem oralen Gewicht- und Diabetes-Kandidaten, wird seinen Marktanteil beschleunigen. Entscheidend ist, dass Orforglipron einem schnelleren als üblicherweise Verfahren durch die Aufsichtsbehörden unterzogen wurde – ein bedeutender Vorteil gegenüber Medikamenten, die von Unternehmen wie Novo Nordisk und Pfizer entwickelt wurden. Die Phase-3-Studienergebnisse von Eli Lilly für Orforglipron waren besonders beeindruckend und zeigten einen durchschnittlichen Gewichtsverlust von 28,7 % bei der höchsten Dosis. Darüber hinaus entwickelt Eli Lilly Retatrutid, das bereits in Phase-3-Studien bemerkenswerte Wirksamkeit gezeigt hat und einen erheblichen durchschnittlichen Gewichtsverlust erzielt hat. Diese Pipeline vielversprechender Medikamente positioniert Eli Lilly als fühler Akteur in der boomenden Anti-Obesity-Markt. Der Artikel geht auf Bedenken hinsichtlich der Bewertung von Eli Lilly ein und weist darauf hin, dass der Aktienkurs mit 33-fachem Vorjahresgewinn liegt, was höher ist als der Durchschnitt für den Gesundheitssektor (18,2). Die Analysten argumentieren jedoch, dass diese Prämie durch das robuste Umsatz- und Gewinnwachstum des Unternehmens gerechtfertigt ist, mit einem Verhältnis von Kurs auf Gewinn zu Wachstum von 0,98. Der Gesamtausblick ist, dass Eli Lilly in Spitzenform ist, starke kurz- und mittelfristige Perspektiven hat und ein großartiger Investment für 2026 und darüber hinaus sein könnte. --- Would you like me to translate any specific part or generate a different style of translation?
11.01.26 14:05:04 Wichtige Gesundheitsnachrichten der Woche: Bei AbbVie, UnitedHealth und Novo Nordisk steht die Aufmerksamkeit im Fokus.
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** **Zusammenfassung (maximal 600 Wörter)** Die Wall Street erlebte eine positive Woche, wobei die wichtigsten US-Aktienindizes neue Rekordhöhen erreichten. Der S&P 500, der Dow Jones und der Nasdaq Composite gewannen an Wert, hauptsächlich aufgrund ermutigender Arbeitsmarktdaten und der Entscheidung des Obersten Gerichtshofs, sich nicht für die Zölle von Präsident Trump zu äußern. Der S&P 500 schloss bei 6.966,28 Punkten, der Dow bei 49.504,07 Punkten und der Nasdaq bei +0,8 %. Die Wochengewinne beliefen sich auf 1,6 %, 2,3 % bzw. 1,9 %. Der Gesundheitssektor profitierte besonders, wobei der S&P 500 Health Care Index (XLV) um 1,5 % stieg. Mehrere einzelne Gesundheitsaktien verzeichneten deutliche Gewinne, insbesondere Centene (+11,56 %), Moderna (+11,15 %), Align Technology (+10,74 %), Bio-Techne (+10,14 %) und Charles River Laboratories International (+9,13 %). Umgekehrt sanken UnitedHealth (-5,84 %), AbbVie (-4,03 %), DaVita (-2,67 %), Cardinal Health (-2,24 %) und Eli Lilly (-1,56 %). Mehrere wichtige Entwicklungen im Gesundheitswesen wurden hervorgehoben. Novo Nordisk brachte sein Wegovy-Tablettenpräparat auf den Markt, ein neues orales GLP-1-Medikament zur Gewichtsabnahme, zu einem monatlichen Preis von 149 US-Dollar für Dosierungen von 1,5 mg und 4 mg, wobei höhere Dosierungen zu 299 US-Dollar pro Monat erhältlich waren. Der Öffentlichkeitsbeauftragte des Unternehmens, Jennifer Duck, trat Novo Nordisk nach über sechs Jahren bei dem Unternehmen zurück. AbbVie gab einen erheblichen Vorablast von 1,3 Milliarden US-Dollar aufgrund von in-process Research and Development (IPR&D) und Meilensteinkosten bekannt, was sich auf die erwarteten Quartalsergebnisse auswirkte. Dies folgt auf eine zuvor angekündigte 2,7 Milliarden US-Dollar hohe Charge im Zusammenhang mit IPR&D und Meilensteinen. Darüber hinaus ist das Private-Equity-Unternehmen TPG kurz vor dem Abschluss eines Kaufs des Geschäftsbereiches Optum UK von UnitedHealth für über 1 Milliarde Pfund (1,4 Milliarden US-Dollar) – der EMIS, einem wichtigen Anbieter von elektronischen Patientenakten, der 2023 von UnitedHealth erworben wurde. Bank of America berät TPG bei diesem Deal. Schließlich kündigte Präsident Donald Trump an, mit allen 14 US-Versicherungsunternehmen zu treffen, um Druck auf sie auszuüben, um die Gesundheitskosten für Amerikaner zu senken. Dies folgt auf deutliche Erhöhungen der Prämien für ACA-Pläne (Affordable Care Act) aufgrund der Auslaufung der COVID-Ära-Steuergutschriften. Die Gesamtmarktperformance deutet auf weiterhin bestehendes Investorenvertrauen im Gesundheitssektor hin, trotz anhaltender Herausforderungen im Zusammenhang mit steigenden Gesundheitskosten und regulatorischen Veränderungen.
10.01.26 19:56:00 Wird die Chevron Aktie 2026 205 Dollar erreichen?
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** **Zusammenfassung (maximal 600 Wörter):** Chevron Corporation (CVX), das einzige westliche Unternehmen, das derzeit Öl aus Venezuela fördern darf, erlebte diese Woche aufgrund der anhaltenden US-Beteiligung an der politischen Situation des Landes erhebliche Marktschwankungen. Die Aktie fiel stark, nachdem die unerwartete Verhaftung von Nicolás Maduro stattfand, und verdeutlicht die prekäre Position von Chevron. Chevron ist derzeit für etwa 20 % der venezolanischen Rohölproduktion verantwortlich und positioniert sich somit als wichtiger Begünstigter, wenn die lange Zeit stillgelegte Ölindustrie des Landes wiederbelebt wird. Analysten sind jedoch zunehmend skeptisch und glauben, dass die Übersetzung politischer Dynamik in nachhaltiges Produktionswachstum ein deutlich längerer Prozess sein wird als derzeit erwartet. Die genaue Form einer Regierung nach Maduro und der Umfang der US-Beteiligung sind wesentliche Unsicherheiten, die die Zeitrahmen hochspekulativ machen. Trotz dieser Unsicherheiten verfolgt Chevron aktiv seine Interessen. Es laufen Gespräche mit der US-Regierung, um Chevron’s Betriebslizenz möglicherweise zu erweitern, was zu erhöhten Rohölexporten zu Chevron-Raffinerien und Drittanbietern führen könnte. Das Unternehmen lädt derzeit Tanks mit der schnellsten Rate seit sieben Monaten, was auf gesteigerte Exportaktivitäten aufgrund des zunehmenden US-Greifens an venezolanischem Rohöl hindeutet. Die zentrale Frage ist, ob Chevron’s venezolanische Operationen ein tragfähiger Wachstumstreiber oder nur eine kurzfristige Erzählung darstellen. **Chevron’s Geschäft:** Chevron ist ein integriertes Energieunternehmen mit Betrieben im Bereich der Exploration und Produktion von Öl und Gas (Upstream) und der Raffinerie (Downstream). Das Unternehmen hat eine Marktkapitalisierung von fast 326,4 Milliarden US-Dollar und die jüngsten Gewinne wurden durch geopolitische Entwicklungen und sein diversifiziertes Portfolio angetrieben. **Aktuelle Leistung & Finanzzahlen:** Im Rahmen seiner Ergebnisse für das dritte Quartal des Geschäftsjahres 2025 übertraf Chevron Erwartungen trotz niedrigerer Rohölpreise. Der Umsatz sank leicht, aber die angepassten Gewinne stiegen aufgrund stärkerer Margen für raffinierte Produkte und eines Rekordproduktionsniveaus von 4,1 Millionen Barreln Rohöl pro Tag, größtenteils dank der Übernahme von Hess. Die Gewinne der Raffinerien stiegen dramatisch, was zu einer deutlichen Erhöhung des freien Cashflows führte. Für die Zukunft prognostizieren Analysten kurzfristigen Druck auf die Gewinne, mit Prognosen für einen Rückgang von 28,64 % im vierten Quartal 2025 und einen Rückgang von 27,46 % für das gesamte Geschäftsjahr 2025. Trotz dieser Prognosen bleibt der Analystenstimmung vorsichtig optimistisch, mit einer Bewertung von „Moderate Buy“ und einem Durchschnittspreisziel von 169,11 US-Dollar, das einen potenziellen Aufwärtsschuss von 4,3 % impliziert. **Analysten-Ausblick:** Bernstein hat sein Kursziel für CVX erhöht, erwartet aber langfristige Stärke trotz kurzfristiger Volatilität. Wall Street hält im Allgemeinen eine Bewertung von „Moderate Buy“, wobei eine beträchtliche Anzahl von Analysten potenzielle Gewinne von 27,1 % nahelegt, wenn die geopolitischen Bedingungen günstig bleiben. --- Would you like me to adjust the translation or focus on a specific aspect of the original text?
09.01.26 23:29:48 Der S&P 500 ist gerade auf ein neues Rekordhoch gestiegen, getrieben von Optimismus in der US-Wirtschaft.
**Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!** **Zusammenfassung (maximal 600 Wörter)** Am Freitag erlebten die Aktienmärkte eine deutliche Rally, wobei der S&P 500 ein neues Allzeithoch erreichte. Auch der Dow Jones und der Nasdaq verzeichneten Gewinne, angetrieben von überraschend starken Wirtschaftsdaten und Unterstützung durch die globalen Märkte. Der Haupttreiber der Rallye war die robuste US-Wirtschaftsdaten. Die Arbeitslosenquote für Dezember sank auf 4,4 %, ein stärkeres Ergebnis als erwartet, und die durchschnittlichen Stundenlöhne stiegen um 3,8 % im Jahresvergleich, übertrafen die Prognosen. Darüber hinaus stieg der von der University of Michigan ermittelte Konsumklima-Index für Januar auf 54,0, was auf eine erhöhte Zuversicht in der US-Wirtschaft hindeutet. Mehrere Sektoren trugen zu den Gewinnen im breiten Markt bei. Halbleiterunternehmen und Datenspeicherhersteller, darunter Sandisk, Intel, Lam Research, Applied Materials, ASML Holding NV, Seagate Technology Holdings Plc, Western Digital, KLA Corp und Micron Technology, erlebten eine deutliche Aufwärtsbewegung. Dies wurde teilweise durch die Stromversorgungsvereinbarungen von Meta Platforms für seine Rechenzentren begünstigt, wodurch Kraftwerksbetreiber wie Vistra angehoben wurden. Darüber hinaus erholte sich der Wohnungssektor, nachdem Präsident Trump die Fannie Mae und Freddie Mac aufforderte, 200 Milliarden Dollar an Hypothekenanleihen zu kaufen. Unternehmen im Bereich Bauen und Zulieferer, wie Builders FirstSource, Lennar, PulteGroup, DR Horton, Toll Brothers und Home Depot, erlebten alle erhebliche Gewinne. Die positive Marktstimmung wurde durch den Nachhall starker Rallyen an globalen Aktienmärkten verstärkt. Der Euro Stoxx 50 erreichte ein neues Rekordhoch, während auch der Shanghai Composite Stock Index in China ein 10,5-Jahres-Hoch erreichte. Trotz der positiven Marktbewegung präsentierten bestimmte Wirtschaftsindikatoren einen etwas vorsichtigeren Ausblick. Die US-Nichtlandesbeschäftigung stieg im Dezember nur um 50.000, unter den Erwartungen von 70.000, und die Beschäftigung für November wurde nach unten korrigiert. Auch die Inflationserwartungen stiegen, was auf anhaltende Inflationsdrucke hindeutet. Die Positionierung der US-Notenbank blieb etwas unklar. Die Marktpreise für einen potenziellen Zinssenkung der Fed bei der kommenden Sitzung am 27.-28. Januar wurden auf nur 5 % geschätzt, was auf eine geringe Wahrscheinlichkeit einer bedeutenden Reduzierung der Zinssätze hindeutet. Die hawkish Bemerkungen von Atlanta Fed Präsident Raphael Bostic, die die Notwendigkeit betonten, die hohe Inflation zu bekämpfen, trugen ebenfalls dazu bei, die Erwartungen zu dämpfen. Die Rentenmärkte wurden von diesen gemischten Daten und der vorsichtigen Haltung der Fed beeinflusst. Die Rendite der 10-jährigen US-Staatsanleihe stieg leicht, und die März-10-jährige T-Notes erlebten einen leichten Rückgang. Der Oberste Gerichtshof verzögerte seine Entscheidung bezüglich Trumps Zölle, was zu Unsicherheiten führte. Auch die europäischen Märkte trugen zum positiven Trend bei, wobei der Euro Stoxx 50 ein neues Rekordhoch erreichte und der deutsche Bund-Ertragsatz stabil blieb. Starke Einzelhandelsumsätze im November und überraschend positive Industrieproduktionszahlen in Deutschland stärkten das Vertrauen der Investoren zusätzlich.